MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology,Annals of Clinical and Translational Neurology

当前位置： X-MOL 学术 › Ann. Clin. Transl. Neur. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology
Annals of Clinical and Translational Neurology ( IF 4.4 ) Pub Date : 2021-08-02 , DOI: 10.1002/acn3.51435
Chihiro Sato ₁ , Nipun Mallipeddi ₁ , Nupur Ghoshal _{1,

2} , Brenton A Wright ₃ , Gregory S Day ₄ , Albert A Davis _{1,

5} , Albert H Kim _{5,

6} , Gregory J Zipfel _{5,

6} , Randall J Bateman _{1,

5,

7} , Audrey Gabelle ₈ , Nicolas R Barthélemy ₁

Affiliation

Tau hyperphosphorylation at threonine 217 (pT217) in cerebrospinal fluid (CSF) has recently been linked to early amyloidosis and could serve as a highly sensitive biomarker for Alzheimer’s disease (AD). However, it remains unclear whether other tauopathies induce pT217 modifications. To determine if pT217 modification is specific to AD, CSF pT217 was measured in AD and other tauopathies.

中文翻译：

MAPT R406W 在没有淀粉样蛋白病理的情况下增加 tau T217 磷酸化

脑脊液 (CSF) 中苏氨酸 217 (pT217) 的 Tau 过度磷酸化最近与早期淀粉样变性有关，并可作为阿尔茨海默病 (AD) 的高度敏感生物标志物。然而，尚不清楚其他 tau 蛋白病是否会诱导 pT217 修饰。为了确定 pT217 修饰是否对 AD 具有特异性，在 AD 和其他 tau蛋白病中测量了 CSF pT217。

更新日期：2021-09-06

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11